ClinicalTrials.gg
WithdrawnNCT04801056Updated May 18, 2022

Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19

A Phase 1 interventional study of TB006 and Placebo in Covid19, sponsored by TrueBinding, Inc.. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-18.

Sponsored by TrueBinding, Inc. · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Difficulty in patient recruitment and will start again if study population increases to allow study feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients. The primary objective of TB006 treatment is to decrease the potential acute severe deterioration in outpatient COVID-19 patients with underlying diseases, such as diabetes, hypertension, and cancer. TB006 has been developed to treat the ambulatory patients with diagnosed mild to moderate COVID-19 who are considered at low risk for severe disease or hospitalization.

Read the detailed description

TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients. The primary objective of TB006 treatment is to decrease the potential acute severe deterioration in outpatient COVID-19 patients with underlying diseases, such as diabetes, hypertension, and cancer. TB006 has been developed to treat the ambulatory patients with diagnosed mild to moderate COVID-19 who are considered at low risk for severe disease or hospitalization.

In the single ascending dose study, the dosages of 5 mg/kg \~ 50 mg/kg will be investigated in patients with mild to moderate COVID-19, and will be administered to patients over 60 minutes after dilution in 0.9% Sodium Chloride Injection, USP (normal saline) to a final volume of 250 mL. The primary objective of the SAD study is to evaluate the safety and tolerability of single ascending doses of TB006 vs placebo administered via i.v. infusion in outpatient patients with mild-to-moderate COVID-19 and to determine the dose recommended for Phase Ib study.

02

Conditions studied

  • Covid19

Browse trials for

03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

TrueBinding, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf).
  2. Age ≥ 18 years
  3. A positive Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection confirmed by polymerase chain reaction (PCR) test or an equivalent test ≤ 3 days before randomization
  4. Patients with mild to moderate COVID-19 experiencing any of the following symptoms:

    • Mild (without shortness of breath or dyspnea): Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms
    • Moderate: Any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with COVID-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (SpO2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute
  5. At low risk for progressing to severe COVID-19 and/or hospitalization.
  6. Adequate organ function at screening as evidenced by:

    • > 10.9 g/dL
    • (ANC) > 1.0 × 10\^9/L
    • > 125 × 10\^9/L
    • (ALT) or aspartate aminotransferase (AST) \< 1.25 × (ULN)
    • > 90 mL/min using the Cockcroft-Gault formula for patients ≥ 18 years of age [Cockcroft 1976]
  7. Normal with of ≤ 450 ms

Exclusion criteria

Exclusion Criteria:

  1. Participation in any other clinical trial of an experimental treatment for COVID-19
  2. Clinical signs indicative of Severe or Critical Illness Severity

    • SEVERE:
    • Any symptom of severe, systematic illness, including moderate illness, shortness of breath, or respiratory distress
    • Clinically suggestive of severe illness with COVID-19, such as respiratory rate ≥ 30 breaths per minute, heart rate ≥ 125 per minute, saturation of oxygen (SpO2) ≤ 93% on room air at sea level, or PaO2/FiO2 \< 300
    • CRITICAL ILLNESS (one of the following):
    • Respiratory failure defined based on resource utilization requiring at least one of the following:

      1. Endotracheal intubation and mechanical ventilation, oxygen delivered by high483 flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates > 20 L/min with fraction of delivered oxygen ≥ 0.5)
      2. Noninvasive positive pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (i.e., clinical need for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation)
    • Shock (defined by systolic blood pressure \< 90 mm Hg, or diastolic blood pressure \< 60 mm Hg or requiring vasopressors)
    • Multi-organ dysfunction/failure
  3. Have a history of a positive SARS-CoV-2 serology test
  4. Evidence of shock (defined by systolic blood pressure \< 90 mm Hg, or diastolic blood pressure \< 60 mm Hg or requiring vasopressors)
  5. Patients who are hospitalized due to COVID-19
  6. Patients who required oxygen therapy due to COVID-19
  7. Patients who required mechanical ventilation or anticipated impending need for mechanical ventilation
  8. Receiving V-V ECMO ≥ 5 days, or any duration of V-A ECMO
  9. Have a history of convalescent COVID-19 plasma treatment
  10. Women who are pregnant or breastfeeding
  11. Male or female of who has plans to become pregnant during the study period and for six months after the clinical study or who is not willing to take appropriate measures (e.g., concomitant use of a spermicidal agent, barrier contraceptive, or/and intrauterine contraceptive)
  12. Viral disease (, , , etc.) other than COVID-19 that are not adequately controlled or require administration of other antiviral agents or medications that could potentially interact with TB006
  13. Patients with a history or current evidence of any concomitant condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's participation and compliance
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    TB006

    During the SAD study, subjects will receive a single dose of TB006 (at the dosage level of 10 \~ 50 mg/kg) administered via i.v. infusion for 60 mins. In addition, a sentinel cohort of 5 mg/kg will be open for enrollment and double-blinded randomization first, with 2 patients randomized to active/TB006 arm, to assess preliminary safety and tolerability of study drug, and to determine cohort expansion and dose escalation. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start.

    Drug: TB006

  • Placebo comparator
    Placebo

    During the SAD study, subjects will receive a single dose of the placebo administered via i.v. infusion for 60 mins. In addition, the corresponding sentinel placebo group will include 1 patient to placebo arm. Upon the completion of sentinel cohort and all subjects are safe and well tolerate study treatment, regular dose escalation will start.

    Other: Placebo

Interventions

  • DrugTB006

    TB006 monoclonal antibody

  • OtherPlacebo

    Placebo i.v. infusion

06

What researchers measure

Primary outcomes

  1. Treatment emergent adverse events

    Evaluated as per DAIDS v2.1

    Time frame: Baseline to Day 85

Secondary outcomes

  1. Pharmacokinetic parameters of TB006: AUC(0-last)

    - Area under the plasma concentration curve over time (hr\*µg/mL)

    Time frame: Day 1 to Day 85

  2. Pharmacokinetic parameters of TB006: Cmax

    - Maximum concentration of TB006 (µg/mL)

    Time frame: Day 1 to Day 85

  3. Pharmacokinetic parameters of TB006: Tmax

    - The amount of time that TB006 is present at the maximum concentration (hours)

    Time frame: Day 1 to Day 85

  4. Pharmacokinetic parameters of TB006: T1/2

    - Half life of TB006 (hours)

    Time frame: Day 1 to Day 85

  5. Immunogenicity

    - Anti-drug antibodies (ADA)

    Time frame: Day 1 to Day 85

  6. Preliminary Efficacy: Viral shedding change

    Change from baseline in viral shedding from Day 1 to Day 28, as measured by RT-qPCR

    Time frame: Day 1 to Day 28

  7. Preliminary Efficacy: Viral shedding change at each visit

    Change from baseline in viral shedding at each visit through Day 28, as measured by RT-qPCR

    Time frame: Baseline to Day 28

  8. Preliminary Efficacy: Time to viral shedding clearance

    Measure the time to viral shedding clearance

    Time frame: Baseline to Day 85

  9. Preliminary Efficacy: Proportion of treated patients with ≥ 1 COVID-19 related medically-attended visit through Day 28

    Proportion of treated patients with ≥ 1 COVID-19 related medically-attended visit through Day 28

    Time frame: Baseline to Day 28

  10. Preliminary Efficacy: Total number of COVID-19 related medically-attended visits

    Number of COVID-19 related medically-attended visits during study

    Time frame: Baseline to Day 28

  11. Preliminary Efficacy: Proportion of treated patients admitted to a hospital due to COVID-19

    Proportion of patients admitted to a hospital by Day 28

    Time frame: Baseline to Day 28

  12. Preliminary Efficacy: Time to sustained clinical recovery from baseline

    Time to sustained clinical recovery from baseline to end of follow-up visits

    Time frame: Baseline to Day 85

  13. Preliminary Efficacy: Clinical improvement from baseline at each visit through Day 28 (in patients with or without underlying comorbidities

    Measured by change in score according to the World Health Organization (WHO) ordinal scale, ranging from 0 (uninfected) to 8 (dead)

    Time frame: Baseline to Day 28

Other outcomes

  1. Pharmacodynamics biomarkers: Troponins

    Change in cardiac biomarkers (ng/mL)

    Time frame: Baseline to Day 28

  2. Pharmacodynamics biomarkers: N-terminal pro B-type natriuretic peptide (NT-proBNP)

    Change in cardiac biomarkers (pg/mL)

    Time frame: Baseline to Day 28

  3. Pharmacodynamics biomarkers: Creatine kinase-MB (CK-MB)

    Change in cardiac biomarkers (ng/mL)

    Time frame: Baseline to Day 28

  4. Pharmacodynamics biomarkers: Change in neutrophil-lymphocyte ratio (NLR)

    Monitor potential inflammation activity

    Time frame: Baseline to Day 28

  5. Pharmacodynamics biomarkers: IL-6

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  6. Pharmacodynamics biomarkers: IL-2

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  7. Pharmacodynamics biomarkers: IL-7

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  8. Pharmacodynamics biomarkers: IL-8

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  9. Pharmacodynamics biomarkers: IL-1β

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  10. Pharmacodynamics biomarkers: IFNgamma

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  11. Pharmacodynamics biomarkers: TNFα

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  12. Pharmacodynamics biomarkers: IL-10

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  13. Pharmacodynamics biomarkers: MIP-1α/β

    - Change in cytokine measurement (pg/mL)

    Time frame: Baseline to Day 28

  14. Pharmacodynamics biomarkers: C-reactive protein (CRP)

    - Change in serum and plasma biomarkers (mg/L)

    Time frame: Baseline to Day 28

  15. Pharmacodynamics biomarkers: Ferritin

    - Change in serum and plasma biomarkers (mg/L)

    Time frame: Baseline to Day 28

  16. Pharmacodynamics biomarkers: D-dimer

    - Change in serum and plasma biomarkers (mg/L)

    Time frame: Baseline to Day 28

  17. Virology

    - Change in viral sequencing, resistance, infectivity using RT-qPCR

    Time frame: Baseline to Day 85

  18. Patient Report Outcomes (PRO): Sponsor developed patient self-report COVID-19 symptom survey (PSRSS-C19)

    - Change from baseline to Day 28 and safety follow-up visit in score ranging from 0 (none) to 3 (severe)

    Time frame: Baseline to Day 85

  19. Patient Report Outcomes (PRO): Patient Global Impression of Severity (PGI-S) survey

    - Change from baseline to Day 28 and safety follow-up visit in score ranging from 0 (non) to 4 (very severe)

    Time frame: Baseline to Day 85

  20. Patient Report Outcomes (PRO): Patient Global Impression of Change (PGI-C) survey

    - Change from baseline to Day 28 and safety follow-up visit in score ranging from 0 (much better) and 4 (much worse)

    Time frame: Baseline to Day 85

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2021, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 16, 2021
StartActual
Jun 1, 2021
Primary completionActual
Sep 1, 2021
CompletionActual
Sep 1, 2021
Last update
May 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04801056
Lead sponsor
TrueBinding, Inc.
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
Jun 1, 2021
Primary completion
Sep 1, 2021
Completion
Sep 1, 2021
Last update
May 18, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TB006

Start the discussion